AR-323

AR-323 is a potent and selective small molecule inhibitor of Checkpoint kinase 1 (Chk1), a serine/threonine kinase that plays a critical role in the DNA damage response and cell cycle regulation. Developed by AstraZeneca, AR-323 has been primarily investigated in preclinical models of metastatic melanoma. The compound exhibits sub-nanomolar potency (IC50 ~0.3 nM) and high selectivity for Chk1 over the related kinase Chk2. Its mechanism of action involves the inhibition of Chk1-mediated S-phase checkpoints, which forces cells—particularly those with high levels of endogenous DNA damage or replicative stress—to bypass critical repair phases and enter mitosis prematurely. This results in mitotic catastrophe and apoptosis. Research indicates that AR-323 possesses significant single-agent activity in melanoma cell lines, and its sensitivity may be predicted by markers of DNA damage, suggesting its potential as a targeted therapy for tumors characterized by high replicative stress.